MTS-109

MTS-109 is a preclinical-stage RNA therapeutic being developed by Metis Pharmaceuticals for the treatment of autoimmune diseases. The candidate is engineered using Metis's proprietary AI-driven platforms: AiRNA, which utilizes artificial intelligence to optimize RNA sequences for enhanced stability and protein expression, and AiLNP, an AI-guided lipid nanoparticle (LNP) delivery system designed to improve delivery efficiency and tissue specificity. While the specific molecular target and mechanism of action for MTS-109 have not been publicly disclosed, the program represents an application of the company's integrated RNA-LNP platform to modulate immune responses in the context of chronic autoimmune pathology.